| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6743798 | BAYER HLTHCARE | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul, 2019
(4 years ago) | |
| US7173037 | BAYER HLTHCARE | Carbamate-substituted pyrazolopyridines |
Dec, 2026
(2 years from now) | |
| US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(9 years from now) | |
| US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(9 years from now) | |
Adempas is owned by Bayer Hlthcare.
Adempas contains Riociguat.
Adempas has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Adempas are:
- US6743798
Adempas was authorised for market use on 08 October, 2013.
Adempas is available in tablet;oral dosage forms.
Adempas can be used as treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening, treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class.
Drug patent challenges can be filed against Adempas from 08 October, 2017.
The generics of Adempas are possible to be released after 18 February, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening; Treatment of adults with persistent/recurrent ...
Dosage: TABLET;ORAL
ADEMPAS family patents
